https://doi.org/10.5812/kowsar.22517006.2626

Serum Leptin in Peritoneal Dialysis: Is It a Useful Biomarker Following Peritonitis?

authors:

avatar David Johnson Department of Nephro , * , avatar David Johnson 2 , *

Department of Nephro, Brisbane, Australia
Department of Nephrology, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Corresponding Authors:
Nephro-Urology Monthly: Vol.4, issue 1; 333-335
published online: December 18, 2011
article type: Editorial
received: October 6, 2011
revised: October 11, 2011
accepted: October 21, 2011

how to cite: Johnson D, Johnson D. Serum Leptin in Peritoneal Dialysis: Is It a Useful Biomarker Following Peritonitis?. Nephro-Urol Mon. 2012;4(1): 333-335. https://doi.org/10.5812/kowsar.22517006.2626.

1

NA

References

  • 1.

    lameire N, Van Biesen W. Epidemiology of peritoneal dialysis: a story of believers and nonbeliever. Nat Rev Nephrol. 2010;6(2):75-82. [PubMed ID: 20010897]. https://doi.org/10.1038/nrneph.2009.210.

  • 2.

    Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl. 2006;103:S3-11.

  • 3.

    Davies SJ, Phillips l, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12(5):1046-51. [PubMed ID: 11316864].

  • 4.

    Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int. 1997;17(1). [PubMed ID: 9068021].

  • 5.

    Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren Replace Ther. 1998;5(3):179-84. [PubMed ID: 9686628].

  • 6.

    Pecoits-Filho R, Stenvinkel P, heimburger o, lindholm B. Beyond the membrane-the role of new PD solutions in enhancing global biocompatibility. Kidney Int Suppl. 2003;88:S124-32. [PubMed ID: 14870886]. https://doi.org/10.1046/j.1523-1755.2003.08814.x.

  • 7.

    Witowski J, Jorres A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit Dial Int. 2005;25(Suppl 3):S31-4. [PubMed ID: 16048252].

  • 8.

    Schambye HT. Effect of different buffers on the biocompatibility of CAPD solutions. Perit Dial Int. 1996;16(Suppl 1):S130-6. [PubMed ID: 8728179].

  • 9.

    Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel KE, et al. BIoKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]. BMC Nephrol. 2004;5:14. [PubMed ID: 15485574]. https://doi.org/10.1186/1471-2369-5-14.